[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ulsan University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":160},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,82,110,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645124","association-between-4d-mri-parameters-and-the-clinical-characteristics-and-prognosis-of-major-chronic-diseases-100645124",false,"NCT07678606","Association Between 4D MRI Parameters and the Clinical Characteristics and Prognosis of Major Chronic Diseases","4D-MRI","Inclusion Criteria:\n\n* Adults aged 19 years and older undergoing clinically indicated Cardiac MRI at Ulsan University Hospital\n* Participants who undergo an additional 4D MRI sequence during the same imaging session\n* Participants who are able to understand the study and provide written informed consent\n\nExclusion Criteria:\n\n* Individuals aged \\\u003C 19 years\n* Individuals with cognitive impairment or communication difficulties unable to provide informed consent\n* Poor-quality MRI images that are not suitable for analysis\n* Individuals deemed inappropriate for study participation by the investigator",true,"ALL","19 Years",{"count":20,"type":21},1000,"ESTIMATED","10 Years","OBSERVATIONAL","Cancer and cardiovascular diseases are among the leading causes of morbidity and mortality worldwide. Advanced imaging techniques such as 4D magnetic resonance imaging (MRI) enable quantitative assessment of hemodynamic and functional parameters beyond conventional imaging. The aim of this study is to evaluate the association between 4D MRI derived parameters and the occurrence, severity, and prognosis of major chronic diseases, and to explore their potential role as imaging biomarkers.",[26,27,28],"Cardiovascular Disease","Cardiac Magnetic Resonance Imaging","Neoplasm",[30,31,27,32],"Cardiovascular disease","Malignancy","Hemodynamic parameters","NOT_YET_RECRUITING","2026-06-24",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":36,"type":21},{"date":40,"type":21},"2046-02-28",{"name":42,"class":43},"Ulsan University Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":44},"100597373","shape-sensing-robotic-assisted-bronchoscopy-for-diagnosis-of-peripheral-pulmonary-nodules-in-korea-100597373","NCT07057648","Shape-Sensing Robotic-Assisted Bronchoscopy for Diagnosis of Peripheral Pulmonary Nodules in Korea","Shape-sensing Robotic-assisted Bronchoscopy (ssRAB) for Diagnosis of Peripheral Pulmonary Nodules: A Prospective Cohort Study in Korea (the ULSAN-ION Study)","ULSAN-ION","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Solid or part-solid peripheral pulmonary nodules confirmed on chest computed tomography (CT)\n* Patients requiring histological diagnosis as determined by the treating physician\n* Patients eligible for bronchoscopy procedure\n* Ability to provide written informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2 or equivalent functional status allowing procedure under sedation or general anesthesia\n\nExclusion Criteria:\n\n* Pure ground glass opacity nodules\n* Bleeding tendency defined as platelet count less than 50,000\u002FμL or International Normalized Ratio (INR) greater than 1.5\n* Severe cardiopulmonary dysfunction precluding deep sedation or general anesthesia\n* Pregnant or breastfeeding women\n* Life expectancy less than 6 months as assessed by the treating physician\n* Inability or unwillingness to provide informed consent\n* Absolute contraindication to bronchoscopy including:\n\n  * Severe hypoxemia (oxygen saturation \\\u003C90% on room air)\n  * Severe pulmonary hypertension\n  * Recent myocardial infarction (within 6 weeks)\n  * Unstable angina\n  * Malignant arrhythmias\n* Participation in another interventional clinical trial that may interfere with study procedures or outcomes",{"count":54,"type":21},100,"6 Months","What is this study about? This study tests a new robotic technology to take tissue samples from lung nodules (small spots in the lungs). Some lung nodules are cancer, but doctors need a tissue sample to know for sure.\n\nWhat is the problem? Current methods to get tissue from lung nodules only work about 7 out of 10 times. When they don't work, doctors may need riskier procedures.\n\nWhat is the new technology? The new technology is called robotic bronchoscopy (ssRAB). It uses a robot with special sensors to guide a thin tube more accurately to lung nodules than current methods.\n\nWho can join? Adults aged 19 or older who have lung nodules that need tissue sampling and are healthy enough for the procedure.\n\nWhat happens? Participants will have the robotic procedure while asleep under anesthesia. The robot guides a thin tube to the lung nodule to take a small tissue sample. Participants are watched for problems and followed for 6 months.\n\nWhat are the risks and benefits? The new technology may be more accurate and safer than current methods. The main risks are small chance of lung collapse or bleeding, similar to regular procedures.\n\nWhy is this important? This study will show if the new robotic technology works well and is safe in Korea. If successful, it could help diagnose lung cancer earlier and more accurately.\n\nThis study will include 100 people at Ulsan University Hospital in Korea.",[58,59,60,61,62],"Lung Nodules","Peripheral Lung Lesions","Pulmonary Nodules","Lung Cancers","Bronchoscopy",[64,65,66,67,68,58,69,70,71,72],"Shape-sensing robotic-assisted bronchoscopy","ssRAB","Robotic bronchoscopy","Peripheral lung nodules","Diagnostic yield","Navigation bronchoscopy","Lung biopsy","Korea","Prospective cohort","RECRUITING","2026-02-10",{"date":76,"type":37},"2026-02-13",{"date":78,"type":37},"2025-07-09",{"date":80,"type":21},"2027-05-31",{"name":42,"class":43},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":107,"leadSponsor":109,"locationsCount":5},"100624153","evaluation-of-the-effectiveness-of-managing-chemotherapy-side-effects-using-epro-and-a-standardized-telenursing-program-for-cancer-patients-100624153","NCT07405931","Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Diagnosed with early or advanced gastric, lung, breast, or colon cancer\n* Starting first-cycle chemotherapy with a new anticancer agent\n* Able to use a smartphone without difficulty\n* Willing to provide informed consent to participate in the study\n\nExclusion Criteria:\n\n* Individuals who have difficulty communicating due to cognitive impairment, visual impairment, hearing impairment, or other reasons\n* Individuals who cannot read, write, or understand Korean\n* Other individuals deemed inappropriate for participation by the investigators",{"count":89,"type":21},414,"INTERVENTIONAL",[92],"NA","This is a multicenter randomized controlled clinical trial designed to evaluate the clinical efficacy and cost-effectiveness of a digital health platform that integrates a symptom reporting and management software with a standardized telenursing program, allowing cancer patients to actively monitor, report, and self-manage chemotherapy-related adverse effects.",[95,96,97,98,99,100,101,102],"Early Gastric Cancer","Advanced Gastric Cancer","Early Lung Cancer","Advanced Lung Cancer","Early Breast Cancer","Advanced Breast Cancer","Early Colon Cancer","Advanced Colon Cancer","2026-02-08",{"date":105,"type":37},"2026-02-12",{"date":78,"type":37},{"date":108,"type":21},"2026-09",{"name":42,"class":43},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":90,"phases":118,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},"100623543","discontinuation-of-antiplatelet-therapy-after-drug-coated-balloon-treatment-100623543","NCT07398001","Discontinuation of Antiplatelet Therapy After Drug-Coated Balloon Treatment","Inclusion Criteria:\n\n1. Adults aged 19 years or older who are able to understand the risks, benefits, and treatment alternatives of the study and who provide written informed consent voluntarily.\n2. Patients who underwent drug-coated balloon treatment at least 12 months prior to enrollment.\n3. Patients who have not experienced major adverse cardiovascular events, including myocardial infarction, stroke, or target vessel revascularization, since the index DCB treatment.\n4. Patients who have not experienced major bleeding since the index DCB treatment.\n5. Patients who are receiving antiplatelet therapy at the time of enrollment.\n\nExclusion Criteria:\n\n1. Patients with concomitant vascular disease requiring long-term antiplatelet therapy.\n2. Patients with non-cardiac comorbid conditions that, in the judgment of the investigator, are associated with a life expectancy of less than 1 year or may result in poor compliance with the study protocol.\n3. Patients who are participating in another drug or coronary device clinical study at the time of enrollment.",{"count":117,"type":21},1042,[92],"The goal of this clinical trial is to evaluate the benefits and risks of discontinuing antiplatelet therapy on clinical outcomes in patients who previously underwent coronary intervention using a drug-coated balloon.\n\nThe main questions it aims to answer are:\n\nDoes stopping antiplatelet therapy after 12 months affect the risk of net adverse clinical events? Does stopping antiplatelet therapy reduce the risk of bleeding compared with continuing treatment?\n\nResearchers will compare patients who discontinue antiplatelet therapy with patients who continue antiplatelet therapy to determine the impact on clinical outcomes during follow-up.\n\nParticipants will:\n\nBe randomly assigned to either discontinue or continue antiplatelet therapy Receive routine clinical follow-up through clinic visits or telephone contacts Be monitored for cardiovascular events and bleeding outcomes over time",[121,122,123],"Percutaneous Coronary Intervention","Antiplatelet Therapy","Drug-coated Balloon",[125,126,127,128,129],"coronary artery disease","drug-coated balloon","percutaneous coronary intervention","antiplatelet therapy","clinical outcomes","2026-02-02",{"date":132,"type":37},"2026-02-09",{"date":105,"type":21},{"date":135,"type":21},"2030-07-31",{"name":42,"class":43},7,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":44},"100469219","identification-of-risk-factors-for-cardiovascular-disease-and-cancer-in-korean-population-a-prospective-cohort-study-100469219","NCT05389956","Identification of Risk Factors for Cardiovascular Disease and Cancer in Korean Population: A Prospective Cohort Study","Inclusion Criteria:\n\n* Men or women aged 19 years and older who underwent a general health screening at the health promotion center of Ulsan University Hospital (Ulsan, Korea)\n* Subjects have to agree to participate by signing a consent\n\nExclusion Criteria:\n\n* Subjects who cannot or reject to sign the consent form.",{"count":145,"type":21},510000,"Cancer and cardiovascular disease are the global leading causes of death. These two disease entities are multifactorial disease that are caused by several factors. The aim of this prospective cohort study was to investigate the status of risk factors profiles and health related behavior in Korean population, and to discover novel risk factors associated with the occurrence of endpoint events.",[148,31,149],"Cardiovascular Diseases","Risk Factor",[30,31,151],"Risk factor","2024-03-18",{"date":154,"type":37},"2024-03-19",{"date":156,"type":37},"2023-01-01",{"date":158,"type":21},"2052-08",{"name":42,"class":43},""]